Featured Articles
-
What Will The Incoming Trump Administration Mean For Drug Patents?
11/21/2024
Megan Chacon, a principal at Fish & Richardson and a member of the firm’s life sciences industry team, answers questions about what a second Trump administration could mean for biopharmaceutical IP and drug patents.
-
Translating Hidden Gems Into Medicines
11/19/2024
Reflecting on 20 years of experience working as a scientist in Big Pharma and biotech, Louise Modis, Ph.D., CSO at Amphista Therapeutics, shares the key elements necessary for successful drug discovery and development.
-
CEO Panel Talks IRA Impact At Galien Forum
11/14/2024
A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far, and what's likely to come in the year ahead.
-
Is Cash Pay The Right Model For Your Medicine?
11/13/2024
A cash pay model for prescription drugs can help biopharmaceutical companies meet consumer expectations. However, the model isn't right for every product; out-of-pocket costs, and a capable pharmacy partner, are two key considerations.
-
From Bike Mechanic To Surgeon To CEO
11/11/2024
InflaRx cofounder and CEO Niels Riedemann, M.D. shares the overarching pillars that have shaped his career as a physician, surgeon, and biopharmaceutical leader.
-
Mimicking The Hollywood Mindset To Develop Drugs In An Era Driven By Capital Markets
11/7/2024
Traditional organizational structures often struggle to adapt to the dynamic nature of drug development; consultant Sid Parulkar offers another approach that borrows from the Hollywood film industry.
-
Partnering To Advance Next Generation Treatments For Breast Cancer
11/5/2024
Disease progression in metastatic breast cancer is a challenge that no single entity can solve alone. Breakthroughs in treatment and patient outcomes require collaborations that leverage expertise, insights, and capabilities across organizations.
-
Science Does Not Sell Itself: Designing A Winning Pivotal Trial
11/1/2024
Pivotal trial design can make or break a new therapy's commercial viability. This article explores how choosing the right patient population, endpoints, and comparator are critical for achieving a favorable outcome and maximizing a therapy's market potential.
-
A Bioethicist Weighs In On Obesity Drugs
10/31/2024
Anne Zimmerman, editor-in-chief of the Columbia University online journal, Voices in Bioethics discusses her concerns over the use of GLP-1 weight loss drugs in the U.S.
-
Where Are They Now? Ironwood Pharmaceuticals
10/31/2024
Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.